| Literature DB >> 33945921 |
Shuang Ren1, Sisi Huang1, Xinqing Ye2, Luhuai Feng1, Yang Lu1, Chaonan Zhou1, Juan Zhao3, Tingting He3, Junwei Wang3, Bixun Li4.
Abstract
Non-small cell lung cancer (NSCLC) patients with oncogenic ROS1 rearrangements would inevitably develop drug resistance and disease progression after receiving targeted oncogene therapy. Here, we present a metastatic lung adenocarcinoma patient harboring a CD74-ROS1 fusion who initially responded to crizotinib and then developed resistance after acquiring a rarely reported BRAF V600E mutation.Entities:
Keywords: BRAF; Crizotinib; ROS1; Resistance
Mesh：
Substances：
Year: 2021 PMID： 33945921 DOI： 10.1016/j.ctarc.2021.100377
Source DB: PubMed Journal: Cancer Treat Res Commun ISSN： 2468-2942